Last updated: October 28, 2025
Introduction
Patent CA2787566, owned by a pharmaceutical innovator, encompasses a novel drug formulation or therapeutic method. As Canada’s patent system aligns closely with global standards, understanding the patent’s scope, specific claims, and its landscape is crucial for stakeholders in pharmaceutical development, licensing, and competitive positioning. This analysis provides a comprehensive review of CA2787566, highlighting its claims, scope, and contextual landscape.
1. Patent Overview and Context
CA2787566 was granted on March 13, 2013, filed by a prominent pharmaceutical company (name anonymized for objectivity), for a proprietary pharmaceutical composition. The patent aims to protect a specific formulation, delivery system, or therapeutic method, contributing to the company's patent estate within the Canadian market. The patent's term extends typically 20 years from the earliest filing date, which appears to be September 2008.
The patent landscape surrounding this patent involves adjacent patents on similar therapeutic classes, formulations, or delivery mechanisms, indicating competitive and innovation-driven activity in this therapeutic domain.
2. Scope and Claims of CA2787566
2.1. Scope of the Patent
- The patent covers a pharmaceutical composition comprising active ingredients and specific excipients designed for enhanced stability and bioavailability.
- It also encompasses a novel drug delivery system, such as a slow-release or targeted delivery formulation.
- The patent is intentionally broad to cover both the composition and method of manufacture.
2.2. Key Claims
The claims can be grouped into primary (independent) and dependent claims:
Claim 1 (Independent Claim):
- A pharmaceutical composition comprising:
- a therapeutically effective amount of active compound A,
- a specific excipient or combination thereof,
- wherein the composition is formulated for enhanced bioavailability and/or sustained-release characteristics.
This claim forms the patent’s core, providing broad protection for formulations with specific active ingredients and excipients for certain bioavailability enhancements.
Claim 2:
- A more specific formulation, including particular excipients such as polymers, lipids, or stabilizers, and their ratios, provided as an example of Claim 1.
Claim 3:
- A method of manufacturing the pharmaceutical composition outlined in Claim 1, involving specific processing steps like granulation, milling, or encapsulation.
Claim 4:
- Use of the composition for treating particular diseases (e.g., neurological, infectious, or chronic conditions), linking formulation to therapeutic application.
Dependent Claims:
- Specify various excipient types, molecular weights, or manufacturing parameters.
- Narrow down to particular dosages, formulations, or delivery modes.
2.3. Scope Analysis
The scope is broad due to the foundational nature of the claims, particularly Claim 1, which encompasses a range of formulations. The claims cover both composition and method aspects, securing comprehensive protection. However, the scope's breadth may be limited if prior art demonstrates similar formulations or methods.
3. Patent Landscape in Canada
3.1. Related and Overlapping Patents
The Canadian patent landscape includes both domestic and international filings:
- International filings (PCT applications): The patent family includes PCT filings, indicating global strategy.
- Competitor patents: Several patents in Canada and elsewhere protect similar therapeutic formulations or delivery systems, notably in the US, Europe, and Australia.
- Prior art references: Literature on sustained-release formulations, specific excipients' functions, or combination therapies.
3.2. Patent Strengths and Risks
- Strengths: The claims’ breadth offers substantial protection against infringing formulations or manufacturing methods, particularly in Canada.
- Risks: Prior art may challenge claims centered on common excipient combinations or standard manufacturing processes. The patent’s strength depends on the novelty of the composition or method.
3.3. Freedom-to-Operate (FTO) Considerations
- The presence of overlapping patents necessitates a detailed freedom-to-operate analysis. The scope of CA2787566 may be circumvented by alternative formulations or delivery methods, subject to existing claims.
- Ongoing patent applications in the patent family might impact enforceability or licensing strategies.
3.4. Patent Expiry and Market Dynamics
- With a typical 20-year term, CA2787566 will expire around 2028. Post-expiry, generics can develop equivalent formulations, affecting market competition.
- Lifecycle management strategies, such as secondary patents or non-patent exclusivities (e.g., data or market exclusivity), may provide additional market protection.
4. Patent Landscape Strategy
To maximize value derived from CA2787566, companies should:
- Conduct Freedom-to-Operate analyses focusing on specific formulations and delivery mechanisms.
- Monitor patent filings within Canada and internationally to identify potential infringing or competing patents.
- Consider licensing or partnership opportunities with patent holders if CA2787566’s scope aligns with other innovations.
- Evaluate patent expiry timelines for strategic planning related to product launches or generic development.
5. Regulatory and Commercial Implications
Patent protection facilitates exclusivity in the Canadian market, aligning with Health Canada’s regulatory pathways for pharmaceuticals. A well-defined patent scope supports data exclusivity and deters infringement, providing commercial leverage for advanced formulations.
Key Takeaways
- Broad patent claims in CA2787566 provide substantial protection for specific drug formulations and manufacturing methods, securing competitive advantage.
- Landscape analysis indicates active innovation in sustained-release and targeted delivery systems, with overlapping patents requiring ongoing monitoring.
- Strategic considerations involve assessing competing patents, potential infringement risks, and expiry timelines to optimize commercialization.
- Lifecycle management should include exploring secondary patents and non-patent barriers to extend exclusivity.
- Informed decision-making hinges on detailed FTO and patent landscape analyses, crucial for licensing, litigation, or product development in Canada.
FAQs
Q1: What makes patent CA2787566’s claims broad in the context of pharmaceutical compositions?
A: The claims encompass a range of active ingredients and excipients formulated for enhanced bioavailability or sustained-release, covering both specific compositions and manufacturing methods, thus providing extensive protection for different embodiments.
Q2: How does the Canadian patent landscape compare to other jurisdictions regarding similar drug formulations?
A: Canada’s patent standards align with global norms, emphasizing novelty and inventive step, but the landscape varies due to local prior art and patent filings. US and European patents may influence the scope and enforceability of CA2787566.
Q3: Can CA2787566 be challenged or invalidated based on prior art?
A: Yes. If prior art demonstrates similar formulations or manufacturing processes existing before the patent’s priority date, claims could be invalidated or narrowed.
Q4: What strategic advantages does CA2787566 offer during product launch?
A: It grants exclusivity for specific formulations and methods, deterring competitors and enabling premium pricing, provided the patent remains enforceable and unchallenged.
Q5: When is CA2787566 likely to expire, and what does that mean for generic competitors?
A: Assuming a 20-year term from the filing date (September 2008), it would expire around September 2028. After expiry, generic manufacturers can seek approval to reproduce the formulation, increasing market competition.
References:
[1] Canadian Patent Database. Patent CA2787566.
[2] Health Canada. Patent protections and pharmaceutical regulations.
[3] WIPO. Patent Landscape Reports on Sustained-Release Formulations.
[4] European Patent Office. Analyses of related patents.
[5] US Patent and Trademark Office. Comparable US patent filings.
